-

Shareholder Alert: Robbins LLP Announces Kingold Jewelry, Inc. (KGJI) Accused of Misleading Shareholders

SAN DIEGO & WUHAN, China--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Kingold Jewelry, Inc. (NYSE: KGJI) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 15, 2018 and June 28, 2020. Kingold designs, manufactures, and sells 24-karat gold jewelry and Chinese ornaments in the People's Republic of China.

If you suffered a loss as a result of Kingold's misconduct, click here.

Kingold Jewelry, Inc. (KGJI) Accused of Misleading Shareholders

According to the complaint, in March 2018, Kingold filed its 2017 annual report on form 10-K in which the Company stated it "allocated significant portion of its inventories as investment in gold and pledged as collateral to secure loans from banks and financial institutions." The Company also attested to its accuracy of financial reporting and disclosure of all fraud. Kingold then reaffirmed these statements in its 2018 10-K. However, on June 29, 2020, Caixan Global published an article revealing "at least some of 83 tons of gold bars used as collateral [by Kingold] turned out to be nothing but gilded copper." As a result of its fraudulent misconduct, three different financial institutions that loaned to Kingold have filed lawsuits against the Company and the Shanghai Gold Exchange disqualified Kingold as a member. On this news, Kingold's share price fell over 24% to close at $0.85 per share.

Kingold Jewelry, Inc. (KGJI) Shareholders Have Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action on behalf of Kingold settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:KGJI

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom